NASDAQ:CASI CASI Pharmaceuticals (CASI) Stock Price, News & Analysis $1.33 0.00 (-0.02%) Closing price 03:17 PM EasternExtended Trading$1.33 0.00 (0.00%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About CASI Pharmaceuticals Stock (NASDAQ:CASI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CASI Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.30▼$1.3950-Day Range$1.18▼$2.0552-Week Range$1.09▼$7.67Volume12,568 shsAverage Volume50,939 shsMarket Capitalization$16.36 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingBuy Company Overview CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China. Read More CASI Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreCASI MarketRank™: CASI Pharmaceuticals scored higher than 83% of companies evaluated by MarketBeat, and ranked 96th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCASI Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about CASI Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CASI Pharmaceuticals is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CASI Pharmaceuticals is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCASI Pharmaceuticals has a P/B Ratio of 11.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CASI Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.33% of the float of CASI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCASI Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CASI Pharmaceuticals has recently decreased by 35.78%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCASI Pharmaceuticals does not currently pay a dividend.Dividend GrowthCASI Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.50 Percentage of Shares Shorted0.33% of the float of CASI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCASI Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CASI Pharmaceuticals has recently decreased by 35.78%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for CASI Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added CASI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CASI Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders21.24% of the stock of CASI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.23% of the stock of CASI Pharmaceuticals is held by institutions.Read more about CASI Pharmaceuticals' insider trading history. Receive CASI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CASI Stock News HeadlinesCASI Pharmaceuticals Inc Valuation - MorningstarJuly 2 at 9:28 PM | morningstar.comMCASI Pharmaceuticals to divest Chinese assets in $20 million dealMay 12, 2025 | msn.comBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.July 3 at 2:00 AM | Crypto 101 Media (Ad)Casi Pharmaceuticals price target lowered to $4 from $6 at H.C. WainwrightApril 10, 2025 | markets.businessinsider.comCASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely BullishApril 3, 2025 | msn.comCASI Pharmaceuticals Full Year 2024 Earnings: US$2.56 loss per share (vs US$2.02 loss in FY 2023)April 2, 2025 | finance.yahoo.comThis CASI Pharmaceuticals Insider Increased Their Holding By 65% Last YearFebruary 6, 2025 | finance.yahoo.comCASI Pharmaceuticals Third Quarter 2024 Earnings: Beats ExpectationsNovember 17, 2024 | finance.yahoo.comSee More Headlines CASI Stock Analysis - Frequently Asked Questions How have CASI shares performed this year? CASI Pharmaceuticals' stock was trading at $2.83 at the beginning of the year. Since then, CASI shares have decreased by 53.0% and is now trading at $1.33. How were CASI Pharmaceuticals' earnings last quarter? CASI Pharmaceuticals Inc. (NASDAQ:CASI) issued its earnings results on Friday, May, 16th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.61) by $0.08. The biotechnology company earned $6.24 million during the quarter, compared to analysts' expectations of $7.39 million. CASI Pharmaceuticals had a negative trailing twelve-month return on equity of 972.55% and a negative net margin of 129.05%. When did CASI Pharmaceuticals' stock split? CASI Pharmaceuticals's stock reverse split on the morning of Wednesday, June 1st 2022.The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of CASI Pharmaceuticals? Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CASI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that CASI Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Arista Networks (ANET), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings5/16/2025Today7/03/2025Next Earnings (Estimated)8/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CASI CIK895051 Webwww.casipharmaceuticals.com Phone861065086063Fax301-315-2437Employees180Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+194.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($2.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.26 million Net Margins-129.05% Pretax Margin-125.26% Return on Equity-972.55% Return on Assets-77.33% Debt Debt-to-Equity RatioN/A Current Ratio0.81 Quick Ratio0.68 Sales & Book Value Annual Sales$28.54 million Price / Sales0.59 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book11.33Miscellaneous Outstanding Shares12,300,000Free Float9,687,000Market Cap$16.72 million OptionableOptionable Beta0.53 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CASI) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CASI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.